Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Atropine eye drop having eye posterior targeting function

A technology of atropine and eye drops, applied in the field of medicine, can solve the problems of high-priced ophthalmology patients, discomfort and infection, retinal detachment, etc.

Inactive Publication Date: 2018-12-25
HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] At present, the eye drops commonly used in clinical practice are difficult to meet the requirements for the treatment of posterior ocular diseases. The traditional administration methods for posterior ocular diseases are systemic administration and intravitreal or subconjunctival injection. concentration to achieve the therapeutic concentration targeted at the back of the eye, there is potential systemic toxicity, intravitreal or subconjunctival injection as an invasive way of administration may cause local discomfort and infection, and is more likely to cause intraocular Risks such as inflammation and retinal detachment, and because of the long treatment time and high price, it cannot be widely used in ophthalmology patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Atropine eye drop having eye posterior targeting function
  • Atropine eye drop having eye posterior targeting function
  • Atropine eye drop having eye posterior targeting function

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022]

[0023] Preparation process: put the prescribed amount of γ-cyclodextrin in a vial, add distilled water to dissolve, add NaCl and polyvinyl alcohol under stirring condition, stir continuously to dissolve, and autoclave at 121°C for 15 minutes to obtain Gamma-cyclodextrin sterile solution, then dissolve atropine in dichloromethane, filter and sterilize with a 0.22 μm filter membrane under sterile conditions, obtain sterilized atropine solid under sterile conditions, The atropine is added into the gamma cyclodextrin solution for stirring, and after continuous stirring to form a suspension, the suspension is freeze-dried. Prepare a buffer solution of potassium dihydrogen phosphate and disodium hydrogen phosphate, autoclave at 121°C for 15 min, and perform aseptic filling. Disperse with a buffer solution before use to obtain atropine eye drops.

Embodiment 2

[0025]

[0026] Preparation process: Take the prescribed amount of γ-cyclodextrin / hydroxypropyl γ-cyclodextrin (80:20) in a vial, add distilled water to dissolve, add NaCl and polyvinyl alcohol under stirring conditions, and continuously stir to dissolve it. Autoclave at 121°C for 15 minutes to obtain a sterile solution containing γ-cyclodextrin, then dissolve atropine in dichloromethane, filter and sterilize with a 0.22 μm filter membrane under sterile conditions, and obtain For the sterilized atropine solid, the atropine is added into the gamma cyclodextrin solution under aseptic conditions for stirring, and after continuous stirring to form a suspension, the suspension is freeze-dried. Prepare a buffer solution of potassium dihydrogen phosphate and disodium hydrogen phosphate, autoclave at 121°C for 15 min, and perform aseptic filling. Disperse with a buffer solution before use to obtain atropine eye drops.

Embodiment 3

[0028]

[0029] Preparation process: Put the prescribed amount of γ-cyclodextrin / hydroxypropyl γ-cyclodextrin (80:20) in a vial, add distilled water to dissolve, add NaCl and polyvinyl alcohol under stirring conditions, and continuously stir to dissolve it , autoclave at 121°C for 15 minutes to obtain a sterile solution containing γ-cyclodextrin, then dissolve atropine in dichloromethane, filter and sterilize with a 0.22 μm filter membrane under sterile conditions, and sterilize under sterile conditions After obtaining the sterilized atropine solid, the atropine is added into the gamma cyclodextrin solution under aseptic conditions for stirring, and after continuous stirring to form a suspension, the suspension is freeze-dried. Prepare a buffer solution of potassium dihydrogen phosphate and disodium hydrogen phosphate, autoclave at 121°C for 15 min, and perform aseptic filling. Disperse with a buffer solution before use to obtain atropine eye drops.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an atropine eye drop having an eye posterior targeting function, solving the problem that general eye drops are easy to be diluted by tear and remains in eyes in short time. The atropine eye drop has the advantages that bioavailability of medicines in eyes is increased, medicine distribution in eyes is improved, concentration of medicine in eye posterior sclera and retinais increased, and the eye posterior targeting function is achieved.

Description

technical field [0001] The invention belongs to the field of medicine. In particular, it relates to a back-of-the-eye targeted atropine eye drop capable of increasing the drug content in the back of the eye. Background technique [0002] At present, the eye drops commonly used in clinical practice are difficult to meet the requirements for the treatment of posterior ocular diseases. The traditional administration methods for posterior ocular diseases are systemic administration and intravitreal or subconjunctival injection. concentration to achieve the therapeutic concentration targeted at the back of the eye, there is potential systemic toxicity, intravitreal or subconjunctival injection as an invasive way of administration may cause local discomfort and infection, and is more likely to cause intraocular Risks such as inflammation and retinal detachment, and because of the long treatment time and high price, it cannot be widely used in ophthalmology patients. Therefore, i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/08A61K31/46A61K47/40A61P27/02
CPCA61K9/08A61K9/0048A61K31/46A61K47/40A61P27/02
Inventor 陈玺孙勇军陈若莹侯丽蓓彭姣吕晓倩张福云李晨晨高子彬其他发明人请求不公开姓名
Owner HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com